Clinical Trial

Lorlatinib Continuation Study

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2021-11-22; most recent amendment 2025-12-11.
Status change: Recruiting → Active, Not Recruiting 2024-10-08
Status change: Not Yet Recruiting → Recruiting 2022-01-18
Trial Details
NCT Number NCT05144997
Lead Sponsor Pfizer
Conditions Non-Small-Cell Lung Cancer, NSCLC
Enrollment 76 participants
Start Date 2021-12-28
Primary Completion 2026-12-28 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-17